Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity.
about
Mechanism of action of lenalidomide in hematological malignanciesMechanism of action of immunomodulatory drugs (IMiDS) in multiple myelomaThalidomide analogues as anticancer drugsNovel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic)Vaccines versus immunotherapy: overview of approaches in deciding between optionsRecent clinical studies of the immunomodulatory drug (IMiD) lenalidomideManagement of lower-risk myelodysplastic syndromes without del5q: current approach and future trends.Phase I-II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints.Thalidomide and lenalidomide: Mechanism-based potential drug combinations.Prospects for immunotherapy of malignant disease.Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.).Thalidomide and its derivatives: emerging from the wilderness.The immune microenvironment of myelomaInitial testing of lenalidomide by the pediatric preclinical testing programThe tumor protection effect of high-frequency administration of whole tumor cell vaccine and enhanced efficacy by the protein component from Agrocybe aegerita.Transplantation of Immortalized CD34+ and CD34- Adipose-Derived Stem Cells Improve Cardiac Function and Mitigate Systemic Pro-Inflammatory ResponsesThalidomide and immunomodulatory drugs in the treatment of cancer.Lenalidomide enhances the protective effect of a therapeutic vaccine and reverses immune suppression in mice bearing established lymphomas.Expansion of polyfunctional HIV-specific T cells upon stimulation with mRNA electroporated dendritic cells in the presence of immunomodulatory drugsProperties of thalidomide and its analogues: implications for anticancer therapy.Immunomodulatory drugs.Pharmacotherapy of multiple myeloma.Effective antitumor immunity against murine gliomas using dendritic cells transduced with hTERTC27 recombinant adenovirus.Overview of tumor cell-based vaccines.Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers.Lenalidomide-induced immunomodulation in multiple myeloma: impact on vaccines and antitumor responses.Immunodeficiency and immunotherapy in multiple myeloma.Survival from multiple myeloma in England and Wales up to 2001.Phase II Study of Pomalidomide in Patients with Castration-Resistant Prostate CancerLenalidomide maintenance for high-risk multiple myeloma after allogeneic hematopoietic cell transplantation.Combination immune therapies to enhance anti-tumor responses by NK cells.Drug-mediated and cellular immunotherapy in multiple myeloma.Lenalidomide: a synthetic compound with an evolving role in cancer management.The potential of immunomodulatory drugs in the treatment of solid tumors.Novel agents to improve outcome of allogeneic transplantation for patients with multiple myeloma.Pomalidomide therapy for myeloma.Targeting NF-κB and HIF-1 pathways for the treatment of cancer: part I.Thalidomide: an old drug with new action.Pruritus in cutaneous T-cell lymphoma: a review.T-regulatory cells: key players in tumor immune escape and angiogenesis.
P2860
Q21198872-28C0AAFE-D4AE-4722-B3F8-589B077D649DQ24605861-B7AB68D7-DE8C-4A81-ADF4-546A24511F5FQ24670383-C2C564FB-50C5-44E3-8D00-1353060929A3Q26770391-585A45DC-94C6-4B7A-9A4A-56237F3B2C10Q28085434-5D53305E-EA43-4E14-BD60-A32E308B57ACQ28192646-CA7C560E-08E7-431C-9544-0EA161C66929Q30235355-42F301B2-E3DD-4EF4-A31E-0D70512FA926Q33436535-CA698F6F-4E87-48F7-968F-89177A16DD8EQ34775475-C752BDEB-1A37-49DA-9139-C45C61929796Q35041705-99F2CF47-E85E-421F-AFBB-B97EC7033B98Q35064910-260590E7-ED2A-4334-B994-27D23BA89876Q35107977-60C58B78-09B8-419C-BAA6-475642D43287Q35603152-F5A38F45-C37B-42A9-9472-DB551E8F3B58Q35861457-03AD7D07-FA1F-486D-817F-3B96C027D3E3Q35870629-C45CEFFC-CABE-4ED0-9BC7-3082BD9DB769Q35913001-5369B58C-26FD-414F-9A4B-13B7286C1D86Q36040871-6D8FEB6D-0A93-49B7-87F5-0D1EBDA427A0Q36090011-E8027763-6FB5-4C5C-A17D-D8E27FE51E8BQ36154837-AA98144D-C793-459E-9536-70DF0D700024Q36250757-E17C830A-9B70-4753-925C-FF5778C0A1B2Q36321396-36587E25-C0A1-4F1D-9624-F3D0B7CF0539Q36429735-EC69CAD7-2D5A-4384-B18F-7904566BA4E2Q36642484-C4D3CD80-6EF0-47C5-91D4-96B967498597Q36684485-72475D63-A962-44CA-A03D-EF3034DF6D08Q36696902-9F5D6755-2800-42FC-A914-2289E7EA3A98Q36806619-A19475D8-C81A-47E9-BF41-B72DC6DCB1E1Q36904977-C6584CBF-C2E6-4A8A-ABAD-6ACFE8DB612AQ36917738-02B9927F-5D16-4383-B6C4-C11E033ED802Q37137426-3F9B7BDF-469A-4635-857E-DB3F84B74A8EQ37282307-DCBF0114-0B98-41AA-934F-7D94A0EB7EE6Q37408550-FD76E7B1-73BA-4EA0-A2DF-07E10A0D0B6CQ37773257-3C0C7EB4-7CF8-40C9-BB49-6A6CA6F6E8C9Q37791617-4E0205B1-D929-4776-8142-64C861937CD1Q37797475-A01F8376-94D7-4857-9735-4FBD440ABD07Q37822742-0DA70AB8-C6B9-45F6-98F4-FF0A8B0F843DQ37854067-6C614A09-535D-4DB6-AAA3-2283A027EABAQ37882459-C0BF7D5F-1D77-4C3B-986F-1C2F3C0FD66FQ37974744-475B8561-718F-4F1C-BCFF-100D20153BCEQ37979593-EA28527A-C87E-4289-B24C-DEB8A283263EQ38006901-A0B343FD-46B9-44A8-A32D-CB325FD520F0
P2860
Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Protective antitumor immunity ...... y increased Th1-type immunity.
@en
Protective antitumor immunity ...... y increased Th1-type immunity.
@nl
type
label
Protective antitumor immunity ...... y increased Th1-type immunity.
@en
Protective antitumor immunity ...... y increased Th1-type immunity.
@nl
prefLabel
Protective antitumor immunity ...... y increased Th1-type immunity.
@en
Protective antitumor immunity ...... y increased Th1-type immunity.
@nl
P2093
P1476
Protective antitumor immunity ...... y increased Th1-type immunity.
@en
P2093
Angus G Dalgleish
David I Stirling
George W Muller
J Blake Marriott
Keith Dredge
Roger Chen
Stephen M Todryk
P304
P356
10.4049/JIMMUNOL.168.10.4914
P407
P577
2002-05-01T00:00:00Z